S-Glyn™ : Optimizing N-Glycan profiles and their effector functions using a Design-of-Experiments approach
December 17, 2023
Share
Resource Library
Whitepapers
S-Glyn™ : Optimizing N-Glycan profiles and their effector functions using a Design-of-Experiments approach
Registered December 18, 2023 | Modified December 27, 2023
LINKEDIN
FACEBOOK
Clear understanding of a molecule's N-glycan profiles and their effector functions is fundamental for successful IND journey, given that glycosylation during cell culture can impact the biological activity of the drug substance.
In this whitepaper, Junyong Park, Lead Scientist in Upstream Development highlights how our proprietary platform, S-Glyn™ evaluates N-glycan profiles and optimizes effector functions by leveraging the DoE approach, resulting in streamlined development timelines.
Clear understanding of a molecule's N-glycan profiles and their effector functions is fundamental for successful IND journey, given that glycosylation during cell culture can impact the biological activity of the drug substance.
In this whitepaper, Junyong Park, Lead Scientist in Upstream Development highlights how our proprietary platform, S-Glyn™ evaluates N-glycan profiles and optimizes effector functions by leveraging the DoE approach, resulting in streamlined development timelines.
Samsung Biologics Co. Ltd. published this content on 17 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 December 2023 00:37:38 UTC.
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.